Morgan Stanley reiterated an Overweight rating and $1,247 price target on Regeneron (REGN) after the Federal Circuit issued an order to temporarily enjoin Amgen (AMGN) from launching its Eylea biosimilar until further notice. The firm noted that the West Virginia judge denied Regeneron’s request for a preliminary injunction against bEylea, though in an emergency motion filed yesterday by Regeneron, it indicates that “Amgen informed its customers that it intends to launch its biosimilar ‘at risk,’ and that it will be available as early as October 1st.” The firm expects events to evolve quickly over the next few weeks and will continue to monitor the appeal docket “closely.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen data from rocatinlimab in AD ‘look unimpressive,’ says Baird
- Amgen says HORIZON Phase 3 achieves ‘statistically significant’ improvement
- Amgen disclosed ‘underwhelming’ rocatinlimab data, says Leerink
- Amgen’s (AMGN) Drugs Show Promise in Phase 3 Trials
- Amgen announces approval of TEPEZZA to treat CAS or TED in Japan